Titan Pharmaceuticals has bagged Food and Drug Administration’s (FDA) clearance for its Investigational Drug Administration (IND) application for nalmefene Implant, an opioid antagonist, for a Phase 1 study. This drug is intended to protect adults suffering from Opioid Use Disorder (OUD) from relapse following opioid detoxification. President and Chief Operating Officer of Titan says that clearance of their IND is a breakthrough in the production of long-term treatment options in medicine of addiction.
Read More from PRNewswire
English